These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27649683)

  • 1. First reported use of drug-coated balloon for bioresorbable in-scaffold restenosis.
    Latini RA; Buccheri D; Cortese B
    Catheter Cardiovasc Interv; 2017 Mar; 89(4):676-678. PubMed ID: 27649683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
    Ormiston JA; Serruys PW; Onuma Y; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Garcia-Garcia HM
    Circ Cardiovasc Interv; 2012 Oct; 5(5):620-32. PubMed ID: 23048057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unfavorable bioresorbable vascular scaffold resorption, a cause of restenosis?
    Ishida K; Giacchi G; Brugaletta S; García-Álvarez A; Sabaté M
    Cardiovasc Revasc Med; 2016 Dec; 17(8):571-573. PubMed ID: 27345841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography.
    Gomez-Lara J; Brugaletta S; Farooq V; Onuma Y; Diletti R; Windecker S; Thuesen L; McClean D; Koolen J; Whitbourn R; Dudek D; Smits PC; Chevalier B; Regar E; Veldhof S; Rapoza R; Ormiston JA; Garcia-Garcia HM; Serruys PW
    JACC Cardiovasc Interv; 2011 Dec; 4(12):1271-80. PubMed ID: 22192368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioresorbable vascular scaffold restenosis: intravascular imaging evaluation.
    Fabris E; Kilic ID; Caiazzo G; Serdoz R; Foin N; Sinagra G; Di Mario C
    J Cardiovasc Med (Hagerstown); 2016 Dec; 17 Suppl 2():e132-e135. PubMed ID: 26599682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe Neointimal Hyperplasia of Neoplastic Carina Following Bioresorbable Scaffold Implantation Using T-Stenting and Small Protrusion Technique: Insights From Optical Frequency Domain Imaging.
    Kawamoto H; Ruparelia N; Figini F; Latib A; Colombo A
    JACC Cardiovasc Interv; 2015 Nov; 8(13):e207-9. PubMed ID: 26476605
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug-coated balloon for recurrent in-stent restenosis treatment: A suitable strategy.
    Piraino D; Buccheri D; Cimino G; Andolina G
    Int J Cardiol; 2016 Oct; 221():1084-6. PubMed ID: 27448537
    [No Abstract]   [Full Text] [Related]  

  • 8. Early Collapse of a Magnesium Bioresorbable Scaffold.
    Cubero-Gallego H; Vandeloo B; Gomez-Lara J; Romaguera R; Roura G; Gomez-Hospital JA; Cequier A
    JACC Cardiovasc Interv; 2017 Sep; 10(18):e171-e172. PubMed ID: 28935085
    [No Abstract]   [Full Text] [Related]  

  • 9. Feasibility and efficacy of bioresorbable vascular scaffolds use for the treatment of in-stent restenosis and a bifurcation lesion in a heavily calcified diffusely diseased vessel.
    Naganuma T; Costopoulos C; Latib A; Sato K; Miyazaki T; Colombo A
    JACC Cardiovasc Interv; 2014 May; 7(5):e45-6. PubMed ID: 24746654
    [No Abstract]   [Full Text] [Related]  

  • 10. The Absorb Limits.
    Gómez Menchero AE; Camacho Freire SJ; Díaz Fernández JF; Roa Garrido J; León Jiménez J; Cardenal Piris R
    J Invasive Cardiol; 2016 Oct; 28(10):E122-E123. PubMed ID: 27705895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neointimal proliferation is associated with clinical restenosis 2 years after fully bioresorbable vascular scaffold implantation.
    Indolfi C; Mongiardo A; Spaccarotella C; Caiazzo G; Torella D; De Rosa S
    Circ Cardiovasc Imaging; 2014 Jul; 7(4):755-7. PubMed ID: 25027457
    [No Abstract]   [Full Text] [Related]  

  • 12. Restenosis of Coronary Bioresorbable Vascular Scaffolds.
    Alfonso F; García-Guimaraes M
    Rev Esp Cardiol (Engl Ed); 2017 Jul; 70(7):527-531. PubMed ID: 28285939
    [No Abstract]   [Full Text] [Related]  

  • 13. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
    Serruys PW; Onuma Y; Ormiston JA; de Bruyne B; Regar E; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Miquel-Hebert K; Rapoza R; García-García HM
    Circulation; 2010 Nov; 122(22):2301-12. PubMed ID: 21098436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stent coverage and neointimal proliferation in bare metal stents postdilated with a Paclitaxel-eluting balloon versus everolimus-eluting stents: prospective randomized study using optical coherence tomography at 6-month follow-up.
    Poerner TC; Otto S; Gassdorf J; Nitsche K; Janiak F; Scheller B; Goebel B; Jung C; Figulla HR
    Circ Cardiovasc Interv; 2014 Dec; 7(6):760-7. PubMed ID: 25371536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rotational Atherectomy Combined With Bioresorbable Vascular Scaffold Implantation: A Feasible Approach for Recurrent In-stent Restenosis When Other Therapies Failed.
    Pereira-da-Silva T; Patrício L; Cruz Ferreira R
    J Invasive Cardiol; 2015 Jul; 27(7):E143-5. PubMed ID: 26136289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
    Verheye S; Ormiston JA; Stewart J; Webster M; Sanidas E; Costa R; Costa JR; Chamie D; Abizaid AS; Pinto I; Morrison L; Toyloy S; Bhat V; Yan J; Abizaid A
    JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fully bioresorption of an Absorb bioresorbable vascular scaffold after scaffold restenosis.
    Goncalves-Ramírez LR; Gutiérrez H; Rojas P; Cortés C; Serrador A; Ramos B; Toro J; Amat-Santos IJ; San Román JA
    Cardiol J; 2019; 26(2):209-211. PubMed ID: 31032876
    [No Abstract]   [Full Text] [Related]  

  • 19. Paclitaxcel-coated balloon plus bare metal stent vs. sirolimus-eluting stent in de novo lesions: an IVUS study.
    Fischer D; Scheller B; Schäfer A; Klein G; Böhm M; Clever Y; Cremers B
    EuroIntervention; 2012 Aug; 8(4):450-5. PubMed ID: 22917728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late Malapposition After Bare-Metal Stent, But Not Bioresorbable Scaffold: Insights on Intraindividual Heterogeneity in Plaque and Device Response.
    Cortese B; Buccheri D; Silva Orrego P; Biondi-Zoccai G
    J Invasive Cardiol; 2015 Aug; 27(8):E171-2. PubMed ID: 26232021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.